Irinotecan Glenmark (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a topoisomerase I inhibitor. It binds to the topoisomerase I‑DNA complex and prevents the re‑ligation of single‑strand DNA breaks that occur during replication. This leads to accumulation of DNA damage, triggering apoptosis and death of rapidly dividing cancer cells.

The dosing schedule for Irinotecan Glenmark is determined by the prescribing oncologist based on individual patient factors such as body surface area, disease status, and prior therapies. The prescriber selects the appropriate infusion rate and cycle length in accordance with established clinical guidelines.

Safety data for Irinotecan in pregnancy and lactation are limited, and the drug is generally contraindicated because it may cause fetal harm and is excreted in breast milk. Women of child‑bearing potential should use effective contraception and discuss potential risks with their healthcare provider.

Submit an enquiry on the Irinotecan Glenmark product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a mechanism distinct from fluoropyrimidines or oxaliplatin. It is often combined with 5‑FU and leucovorin (FOLFIRI) and provides efficacy in patients who have progressed on oxaliplatin‑based regimens, complementing other agents rather than replacing them.

Store at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the vial in a controlled environment, avoid freezing, and handle with aseptic technique during preparation for intravenous infusion.

Irinotecan Glenmark is supplied as an intravenous solution that must be diluted according to the product label and infused over a prescribed period, typically 30‑90 minutes, under the supervision of qualified healthcare professionals in a clinical setting.

The most critical adverse events include severe neutropenia with infection risk, life‑threatening diarrhea (including colitis), cholinergic syndrome, and rare hypersensitivity reactions. Patients should be monitored closely for signs of infection, dehydration, abdominal pain, and managed promptly according to clinical protocols.

Contraindications include patients with known hypersensitivity to irinotecan or its excipients, those with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment. Caution is also advised for individuals with UGT1A1 polymorphisms that increase the risk of toxicity.